Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...
Brookfield Asset Management is considering a €6.45 billion ($6.9 billion) bid for Grifols SA, with the drug maker’s board set ...
ADRs fell ~6% on Tuesday after its board of directors declined to recommend Brookfield Asset Management's (NYSE:BAM) ...
Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the ...
The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.
Brookfield Asset Management Ltd. is considering a €6.45 billion (US$6.9 billion) bid for Grifols SA, with the drug maker’s ...
Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board ...
A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...
GigaGen announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first ...
A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
A Spanish court on Tuesday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” information about Spanish pharmaceutical firm Grifols, causing its shares to ...